AIRNA is pioneering the discovery and development of RNA editing therapeutics to deliver on the promise of genetically defined medicines for patients with rare and common diseases. RNA editing is poised to lead the next generation of RNA therapeutics by targeting diseases not accessible through other approaches with a medicine that can be conveniently re-dosed and manufactured. AIRNA’s founders, Thorsten Stafforst (University of Tübingen) and Jin Billy Li (Stanford University), were the first to elucidate a therapeutic approach for precise editing of RNA. AIRNA has advanced this groundbreaking research to establish the RESTORE+TM RNA editing platform to restore patients’ health. AIRNA is advancing its first therapeutic program, a best-in-class product candidate to treat the inherited genetic disease alpha-1 antitrypsin deficiency (AATD), as well as a pipeline of therapeutic candidates to address multiple diseases with high unmet need. Initial financing of the company was led by ARCH Venture Partners, with participation from ND Capital, Fast Track Initiative (FTI), Novalis, and Codon Capital. AIRNA has headquarters in Cambridge, MA, with research operations in Tübingen, Germany.
